This study is completed in the United States, in Australia, in France, .... It is testing RO4917838 for schizophrenia.
SchizophreniaDrugOver 18 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether RO4917838 may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive RO4917838, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in Australia, and in Colombia.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: December 11, 2010
Recruitment status
Completed
Enrollment listed in the registry
629
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, France, ...
Age range
Over 18 Years
Official registry ID
NCT01192867
Official title
A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
Akademiska Sjukhuset; Psykosvård och rättspsykiatrisk vård
Uppsala
Site status: Not listed — confirm with the team
United Kingdom · 3 sites
Royal Edinburgh Hospital; Psychiatry
Edinburgh
Site status: Not listed — confirm with the team
Institute of Pyschiatry
London
Site status: Not listed — confirm with the team
Wareneford Hospital
Oxford
Site status: Not listed — confirm with the team
United States · 27 sites
K&S Professional Research Services LLC
Little Rock, Arkansas
Site status: Not listed — confirm with the team
Advanced Research Center Inc.
Anaheim, California
Site status: Not listed — confirm with the team
Comprehensive Clinical Development- Cerritos CA
Cerritos, California
Site status: Not listed — confirm with the team
Diligent Clinical Trials Inc
Downey, California
Site status: Not listed — confirm with the team
Care Research Center
La Palma, California
Site status: Not listed — confirm with the team
Pasadena Research Institute
Pasadena, California
Site status: Not listed — confirm with the team
CNRI - Los Angeles, LLC
Pico Rivera, California
Site status: Not listed — confirm with the team
Pharmax Research Clinic Inc.
Miami, Florida
Site status: Not listed — confirm with the team
Northwest Behavioral Research Center
Marietta, Georgia
Site status: Not listed — confirm with the team
American Medical Research, Inc
Oak Brook, Illinois
Site status: Not listed — confirm with the team
University of Iowa College of Medicine; Psychiatry Research
Iowa City, Iowa
Site status: Not listed — confirm with the team
Clinical Insights, Inc.
Glen Burnie, Maryland
Site status: Not listed — confirm with the team
St Louis Clinical Trials
St Louis, Missouri
Site status: Not listed — confirm with the team
Ocean Rheumatology
Toms River, New Jersey
Site status: Not listed — confirm with the team
CRI Worldwide LLC
Willingboro, New Jersey
Site status: Not listed — confirm with the team
Raymond G. Murphy VA Medical Center
Albuquerque, New Mexico
Site status: Not listed — confirm with the team
Behavioral Medical Research of Brooklyn
Brooklyn, New York
Site status: Not listed — confirm with the team
Comprehensive NeuroScience
Fresh Meadows, New York
Site status: Not listed — confirm with the team
North Carolina Psychiatric Research Center
Raleigh, North Carolina
Site status: Not listed — confirm with the team
UC Health Clinical Trials Office
Cincinnati, Ohio
Site status: Not listed — confirm with the team
Belmont Center for Comprehensive Treatment; Research
Philadelphia, Pennsylvania
Site status: Not listed — confirm with the team
Claghorn-Lesem Research Clinic, Inc.
Bellaire, Texas
Site status: Not listed — confirm with the team
FutureSearch Clinical Trials, LP
Dallas, Texas
Site status: Not listed — confirm with the team
Pillar Clinical Research LLC
Dallas, Texas
Site status: Not listed — confirm with the team
Family Psychiatry of the Woodlands P.A.
The Woodlands, Texas
Site status: Not listed — confirm with the team
Pacific Institute of Medical Sciences
Bothell, Washington
Site status: Not listed — confirm with the team
Eastside Therapeutic Resource
Kirkland, Washington
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01192867. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Placebo, RO4917838, Antipshychotics (Standard of Care). Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Hoffmann-La Roche, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
